AML breakthrough: trial tests stopping treatment for patients in remission
NCT ID NCT06557421
Summary
This study is testing whether patients with acute myeloid leukemia (AML) who have responded well to venetoclax-azacitidine treatment can safely stop taking these drugs after 12 months while maintaining their remission. The trial will closely monitor 50 patients who stop treatment to see if their cancer stays away without medication. Researchers will compare these patients to similar patients from past medical records to determine if treatment discontinuation is effective and safe.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Institut Paoli-Calmettes
RECRUITINGMarseille, 13273, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.